CDKN1A as a target of senescence in heart failure: insights from a multiomics study

Rutao Bian1,2, Li Zhang1,2, Dongyu Li1,2

  • 1Department of Cardiology, Zhengzhou Hospital of Traditional Chinese Medicine, Zhengzhou, Henan, China.

Frontiers in Pharmacology
|November 8, 2024
PubMed

Insights

This study reveals that CDKN1A is causally linked to heart failure (HF) by promoting cardiomyocyte senescence. Findings identify CDKN1A as a therapeutic target for developing novel HF drugs.

Area of Science:

  • Cardiology
  • Genetics
  • Molecular Biology

Background:

  • Cardiomyocyte senescence is a key factor in heart failure (HF) pathogenesis.
  • The precise triggers and causes of HF development and progression remain unclear.

Purpose of the Study:

  • To investigate the genetic links between cardiomyocyte senescence and HF.
  • To identify cell senescence-related genes (SRGs) associated with HF using multi-omics data.

Main Methods:

  • Utilized CellAge, SenMayo, and scRNA-seq data to identify SRGs and analyze cardiac cell expression.
  • Employed Mendelian Randomization (MR), including two-sample MR (TSMR) and summary-data-based MR (SMR), to explore causal relationships with HF.
  • Validated findings using Bayesian colocalization, cis-eQTL, cis-mQTL, cis-pQTL analyses, and assessed druggability of therapeutic targets.

Main Results:

  • Identified 39 SRGs in cardiomyocytes, with CDKN1A showing a causal relationship with HF in both discovery and validation sets.
  • Confirmed CDKN1A as a pathogenic gene for HF via SMR, linking its methylation to HF risk loci.
  • Bayesian colocalization and genetic variation analyses supported the results; two potential therapeutic drugs were identified.

Conclusions:

  • Multi-omics data revealed CDKN1A's role in regulating cardiomyocyte senescence.
  • Identified CDKN1A as a potential therapeutic target for HF drug development.
Abstract

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...